<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">37351283</PMID><DateRevised><Year>2023</Year><Month>07</Month><Day>01</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2297-055X</ISSN><JournalIssue CitedMedium="Print"><Volume>10</Volume><PubDate><Year>2023</Year></PubDate></JournalIssue><Title>Frontiers in cardiovascular medicine</Title><ISOAbbreviation>Front Cardiovasc Med</ISOAbbreviation></Journal><ArticleTitle>A case report of vaccine-induced immune thrombotic thrombocytopenia (VITT) with genetic analysis.</ArticleTitle><Pagination><StartPage>1189320</StartPage><MedlinePgn>1189320</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1189320</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fcvm.2023.1189320</ELocationID><Abstract><AbstractText>The emergence of the rare syndrome called vaccine-induced immune thrombocytopenia and thrombosis (VITT) after adenoviral vector vaccines, including ChAdOx1 nCov-19, raises concern about one's predisposing risk factors. Here we report the case of a 56-year-old white man who developed VITT leading to death within 9 days of symptom onset. He presented with superior sagittal sinus thrombosis, right frontal intraparenchymal hematoma, frontoparietal subarachnoid and massive ventricular hemorrhage, and right lower extremity arterial and venous thrombosis. His laboratory results showed elevated D-dimer, C-reactive protein, tissue factor, P-selectin (CD62p), and positive anti-platelet factor 4. The patient's plasma promoted higher CD62p expression in healthy donors' platelets than the controls. Genetic investigation on coagulation, thrombophilia, inflammation, and type I interferon-related genes was performed. From rare variants in European or African genomic databases, 68 single-nucleotide polymorphisms (SNPs) in one allele and 11 in two alleles from common SNPs were found in the patient genome. This report highlights the possible relationship between VITT and genetic variants. Additional investigations regarding the genetic predisposition of VITT are needed.</AbstractText><CopyrightInformation>© 2023 Mendes-de-Almeida, Kehdy, Martins-Gonçalves, Bokel, Grinsztejn, Mouta Nunes de Oliveira, Maia, Hoagland, Wagner Cardoso, Grinsztejn, Siqueira, Kurtz, Bozza and Garcia.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mendes-de-Almeida</LastName><ForeName>Daniela P</ForeName><Initials>DP</Initials><AffiliationInfo><Affiliation>Department of Hematology, Evandro Chagas National Institute of Infectious Diseases, Fundação Oswaldo Cruz (FIOCRUZ), Rio de Janeiro, Brazil.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medical Affairs, Clinical Studies, and Post-Registration Surveillance (DEAME), Institute of Technology in Immunobiologicals/Bio-Manguinhos, Fundação Oswaldo Cruz (FIOCRUZ), Rio de Janeiro, Brazil.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Research Center, Instituto Nacional de Câncer (INCA), Rio de Janeiro, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kehdy</LastName><ForeName>Fernanda S G</ForeName><Initials>FSG</Initials><AffiliationInfo><Affiliation>Laboratório de Hanseníase, Instituto Oswaldo Cruz, Fundação Oswaldo Cruz (FIOCRUZ), Rio de Janeiro, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martins-Gonçalves</LastName><ForeName>Remy</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Laboratory of Immunopharmacology, Instituto Oswaldo Cruz, Fundação Oswaldo Cruz (FIOCRUZ), Rio de Janeiro, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bokel</LastName><ForeName>Joanna</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Hematology, Evandro Chagas National Institute of Infectious Diseases, Fundação Oswaldo Cruz (FIOCRUZ), Rio de Janeiro, Brazil.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Onco-Hematology Unit, Clínica São Vicente, Rio de Janeiro, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grinsztejn</LastName><ForeName>Eduarda</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Medicine, Hematology and Oncology Division, University Hospitals, Case Western University, Cleveland, OH, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mouta Nunes de Oliveira</LastName><ForeName>Patrícia</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Medical Affairs, Clinical Studies, and Post-Registration Surveillance (DEAME), Institute of Technology in Immunobiologicals/Bio-Manguinhos, Fundação Oswaldo Cruz (FIOCRUZ), Rio de Janeiro, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maia</LastName><ForeName>Maria de Lourdes de Sousa</ForeName><Initials>MLS</Initials><AffiliationInfo><Affiliation>Department of Medical Affairs, Clinical Studies, and Post-Registration Surveillance (DEAME), Institute of Technology in Immunobiologicals/Bio-Manguinhos, Fundação Oswaldo Cruz (FIOCRUZ), Rio de Janeiro, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hoagland</LastName><ForeName>Brenda</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Laboratory of Clinical Research on STD/AIDS, Evandro Chagas National Institute of Infectious Diseases Oswaldo Cruz Foundation (FIOCRUZ), Rio de Janeiro, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wagner Cardoso</LastName><ForeName>Sandra</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Laboratory of Clinical Research on STD/AIDS, Evandro Chagas National Institute of Infectious Diseases Oswaldo Cruz Foundation (FIOCRUZ), Rio de Janeiro, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grinsztejn</LastName><ForeName>Beatriz</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Laboratory of Clinical Research on STD/AIDS, Evandro Chagas National Institute of Infectious Diseases Oswaldo Cruz Foundation (FIOCRUZ), Rio de Janeiro, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Siqueira</LastName><ForeName>Marilda M</ForeName><Initials>MM</Initials><AffiliationInfo><Affiliation>Laboratório de Vírus Respiratórios, Exantemáticos, Enterovírus e Emergências Virais, Instituto Oswaldo Cruz, Fundação Oswaldo Cruz (FIOCRUZ), Rio de Janeiro, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kurtz</LastName><ForeName>Pedro</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Intensive Care Department, Instituto D'Or de Pesquisa e Ensino, Rio de Janeiro, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Bozza</LastName><ForeName>Patricia T</ForeName><Initials>PT</Initials><AffiliationInfo><Affiliation>Laboratory of Immunopharmacology, Instituto Oswaldo Cruz, Fundação Oswaldo Cruz (FIOCRUZ), Rio de Janeiro, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Garcia</LastName><ForeName>Cristiana C</ForeName><Initials>CC</Initials><AffiliationInfo><Affiliation>Laboratório de Vírus Respiratórios, Exantemáticos, Enterovírus e Emergências Virais, Instituto Oswaldo Cruz, Fundação Oswaldo Cruz (FIOCRUZ), Rio de Janeiro, Brazil.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Grupo Integrado de Pesquisas em Biomarcadores, Instituto René Rachou, Fundação Oswaldo Cruz (FIOCRUZ-Minas), Belo Horizonte, Brazil.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>05</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Cardiovasc Med</MedlineTA><NlmUniqueID>101653388</NlmUniqueID><ISSNLinking>2297-055X</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ChAdOx1 nCoV-19 vaccine</Keyword><Keyword MajorTopicYN="N">VITT</Keyword><Keyword MajorTopicYN="N">anti-PF4 antibodies</Keyword><Keyword MajorTopicYN="N">genetic predisposition</Keyword><Keyword MajorTopicYN="N">polymorphisms</Keyword><Keyword MajorTopicYN="N">vaccine-induced thrombotic thrombocytopenia</Keyword></KeywordList><CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>3</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>4</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>6</Month><Day>23</Day><Hour>13</Hour><Minute>8</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>6</Month><Day>23</Day><Hour>13</Hour><Minute>7</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>6</Month><Day>23</Day><Hour>10</Hour><Minute>32</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>1</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37351283</ArticleId><ArticleId IdType="pmc">PMC10284151</ArticleId><ArticleId IdType="doi">10.3389/fcvm.2023.1189320</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Greinacher A, Thiele T, Warkentin TE, Weisser K, Kyrle PA, Eichinger S. Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination. N Engl J Med. (2021) 384(22):2092–101. 10.1056/NEJMoa2104840</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2104840</ArticleId><ArticleId IdType="pmc">PMC8095372</ArticleId><ArticleId IdType="pubmed">33835769</ArticleId></ArticleIdList></Reference><Reference><Citation>Pavord S, Scully M, Hunt BJ, Lester W, Bagot C, Craven B, et al. Clinical features of vaccine-induced immune thrombocytopenia and thrombosis. N Engl J Med. (2021) 385(18):1680–9. 10.1056/NEJMoa2109908</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2109908</ArticleId><ArticleId IdType="pmc">PMC10662971</ArticleId><ArticleId IdType="pubmed">34379914</ArticleId></ArticleIdList></Reference><Reference><Citation>Buoninfante A, Andeweg A, Baker AT, Borad M, Crawford N, Dogné JM, et al. Understanding thrombosis with thrombocytopenia syndrome after COVID-19 vaccination. npj Vaccines. (2022) 7(1):141. 10.1038/s41541-022-00569-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41541-022-00569-8</ArticleId><ArticleId IdType="pmc">PMC9643955</ArticleId><ArticleId IdType="pubmed">36351906</ArticleId></ArticleIdList></Reference><Reference><Citation>Greinacher A, Selleng K, Palankar R, Wesche J, Handtke S, Wolff M, et al. Insights in ChAdOx1 nCoV-19 vaccine-induced immune thrombotic thrombocytopenia. Blood. (2021) 138(22):2256–68. 10.1182/blood.2021013231</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood.2021013231</ArticleId><ArticleId IdType="pmc">PMC8483989</ArticleId><ArticleId IdType="pubmed">34587242</ArticleId></ArticleIdList></Reference><Reference><Citation>Campello E, Bulato C, Simion C, Spiezia L, Radu CM, Gavasso S, et al. Assessing clinically meaningful hypercoagulability after COVID-19 vaccination: a longitudinal study. Thromb Haemost. (2022) 122(08):1352–60. 10.1055/a-1788-5206</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/a-1788-5206</ArticleId><ArticleId IdType="pmc">PMC9393084</ArticleId><ArticleId IdType="pubmed">35253140</ArticleId></ArticleIdList></Reference><Reference><Citation>Arepally GM, Ortel TL. Vaccine-induced immune thrombotic thrombocytopenia: what we know and do not know. Blood. (2021) 138(4):293–8. 10.1182/blood.2021012152</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood.2021012152</ArticleId><ArticleId IdType="pmc">PMC8172307</ArticleId><ArticleId IdType="pubmed">34323940</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanack AJ, Bayas A, George G, Abou-Ismail MY, Singh B, Kohlhagen MC, et al. Monoclonal and oligoclonal anti-platelet factor 4 antibodies mediate VITT. Blood. (2022) 140(1):73–7. 10.1182/blood.2021014588</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood.2021014588</ArticleId><ArticleId IdType="pmc">PMC9262283</ArticleId><ArticleId IdType="pubmed">35560046</ArticleId></ArticleIdList></Reference><Reference><Citation>Handtke S, Wolff M, Zaninetti C, Wesche J, Schönborn L, Aurich K, et al. A flow cytometric assay to detect platelet-activating antibodies in VITT after ChAdOx1 nCov-19 vaccination. Blood. (2021) 137(26):3656–9. 10.1182/blood.2021012064</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood.2021012064</ArticleId><ArticleId IdType="pmc">PMC8105122</ArticleId><ArticleId IdType="pubmed">33945605</ArticleId></ArticleIdList></Reference><Reference><Citation>NM_000128.4(F11):c.1304+12G&gt;A and hereditary factor XI deficiency disease [Internet]. National Library of Medicine. (2023). Available at:
https://www.ncbi.nlm.nih.gov/clinvar/RCV001151016.4/ (Accessed March 10, 2023).</Citation></Reference><Reference><Citation>Makris M, Pavord S. Most cases of thrombosis and thrombocytopenia syndrome (TTS) post ChAdOx-1 nCov-19 are vaccine-induced immune thrombotic thrombocytopenia (VITT). Lancet Reg Health Eur. (2022) 12:100274. 10.1016/j.lanepe.2021.100274</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lanepe.2021.100274</ArticleId><ArticleId IdType="pmc">PMC8639457</ArticleId><ArticleId IdType="pubmed">34901913</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen RT.
Updated proposed Brighton collaboration process for developing a standard case definition for study of new clinical syndrome X, as applied to thrombosis with thrombocytopenia syndrome (TTS) [Internet]. (2021). Available at:
https://brightoncollaboration.us/wp-content/uploads/2021/05/TTS-Interim-Case-Definition-v10.16.3-May-23-2021.pdf
(cited October 4, 2021).</Citation></Reference><Reference><Citation>Mouta Nunes de Oliveira P, Mendes-de-Almeida DP, Bertollo Gomes Porto V, Crespo Cordeiro C, Vitiello Teixeira G, Saraiva Pedro R, et al. Vaccine-induced immune thrombotic thrombocytopenia after COVID-19 vaccination: description of a series of 39 cases in Brazil. Vaccine. (2022) 40(33):4788–95. 10.1016/j.vaccine.2022.06.014</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2022.06.014</ArticleId><ArticleId IdType="pmc">PMC9212666</ArticleId><ArticleId IdType="pubmed">35779962</ArticleId></ArticleIdList></Reference><Reference><Citation>Schultz NH, Sørvoll IH, Michelsen AE, Munthe LA, Lund-Johansen F, Ahlen MT, et al. Thrombosis and thrombocytopenia after ChAdOx1 nCoV-19 vaccination. N Engl J Med. (2021) 384(22):2124–30. 10.1056/NEJMoa2104882</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2104882</ArticleId><ArticleId IdType="pmc">PMC8112568</ArticleId><ArticleId IdType="pubmed">33835768</ArticleId></ArticleIdList></Reference><Reference><Citation>See I, Lale A, Marquez P, Streiff MB, Wheeler AP, Tepper NK, et al. Case series of thrombosis with thrombocytopenia syndrome after COVID-19 vaccination-United States, December 2020 to August 2021. Ann Intern Med. (2022) 175(4):513–22. 10.7326/M21-4502</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/M21-4502</ArticleId><ArticleId IdType="pmc">PMC8787833</ArticleId><ArticleId IdType="pubmed">35038274</ArticleId></ArticleIdList></Reference><Reference><Citation>Hickey SE, Curry CJ, Toriello HV. ACMG Practice guideline: lack of evidence for MTHFR polymorphism testing. Genet Med. (2013) 15(2):153–6. 10.1038/gim.2012.165</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/gim.2012.165</ArticleId><ArticleId IdType="pubmed">23288205</ArticleId></ArticleIdList></Reference><Reference><Citation>Deloughery TG, Hunt BJ, Barnes GD, Connors JM, Ay C, Barco S, et al. A call to action: MTHFR polymorphisms should not be a part of inherited thrombophilia testing. Res Pract Thromb Haemost. (2022) 6(4):e12739. 10.1002/rth2.12739</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/rth2.12739</ArticleId><ArticleId IdType="pmc">PMC9175241</ArticleId><ArticleId IdType="pubmed">35702587</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen M, Mao BY, Wang D, Cheng X, Xu CX. Association between rs1801133 polymorphism and risk of adult ischemic stroke: meta-analysis based on case–control studies. Thromb Res. (2016) 137:17–25. 10.1016/j.thromres.2015.11.037</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.thromres.2015.11.037</ArticleId><ArticleId IdType="pubmed">26678951</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeng J, Zeng Q. Correlations between methylenetetrahydrofolate reductase gene polymorphisms and venous thromboembolism: a meta-analysis of 99 genetic association studies. Eur J Prev Cardiolog. (2019) 26(2):120–34. 10.1177/2047487318799467</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/2047487318799467</ArticleId><ArticleId IdType="pubmed">30466296</ArticleId></ArticleIdList></Reference><Reference><Citation>Castelli GP, Pognani C, Sozzi C, Franchini M, Vivona L. Cerebral venous sinus thrombosis associated with thrombocytopenia post-vaccination for COVID-19. Crit Care. (2021) 25(1):137. 10.1186/s13054-021-03572-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13054-021-03572-y</ArticleId><ArticleId IdType="pmc">PMC8039796</ArticleId><ArticleId IdType="pubmed">33845870</ArticleId></ArticleIdList></Reference><Reference><Citation>Fousse M, Schub D, Merzou F, Fassbender K, Sester M, Kettner M, et al. Case report: cerebral sinus vein thrombosis in two patients with AstraZeneca SARS-CoV-2 vaccination. J Neurol. (2022) 269(2):583–6. 10.1007/s00415-021-10731-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-021-10731-2</ArticleId><ArticleId IdType="pmc">PMC8491181</ArticleId><ArticleId IdType="pubmed">34609603</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin-Fernandez L, Gavidia-Bovadilla G, Corrales I, Brunel H, Ramírez L, López S, et al. Next generation sequencing to dissect the genetic architecture of KNG1 and F11 loci using factor XI levels as an intermediate phenotype of thrombosis. PLoS One. (2017) 12(4):e0176301. 10.1371/journal.pone.0176301</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0176301</ArticleId><ArticleId IdType="pmc">PMC5405990</ArticleId><ArticleId IdType="pubmed">28445521</ArticleId></ArticleIdList></Reference><Reference><Citation>Wiewel-Verschueren S, Mulder AB, Meijer K, Mulder R. Factor 11 single-nucleotide variants in women with heavy menstrual bleeding. J Obstet Gynaecol. (2017) 37(7):912–8. 10.1080/01443615.2017.1312303</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/01443615.2017.1312303</ArticleId><ArticleId IdType="pubmed">28609141</ArticleId></ArticleIdList></Reference><Reference><Citation>Campo G, Lunghi B, Pavasini R, Ferraresi P, Punzetti S, Malagù M, et al. Factor XI rs2036914 gene polymorphism and occurrence of adverse events after percutaneous coronary intervention. A prospective evaluation. Int J Cardiol. (2014) 177(2):711–3. 10.1016/j.ijcard.2014.10.014</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijcard.2014.10.014</ArticleId><ArticleId IdType="pubmed">25456690</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryan TAJ, O’Neill LAJ. An emerging role for type I interferons as critical regulators of blood coagulation. Cells. (2023) 12(5):778. 10.3390/cells12050778</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells12050778</ArticleId><ArticleId IdType="pmc">PMC10001161</ArticleId><ArticleId IdType="pubmed">36899914</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>